• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Envista Holdings Corporation

    2/14/25 8:57:25 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care
    Get the next $NVST alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Envista Holdings Corporation

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    29415F104

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29415F104


    1Names of Reporting Persons

    American Century Investment Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,407,790.00
    6Shared Voting Power

    7Sole Dispositive Power

    7,666,991.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,666,991.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    29415F104


    1Names of Reporting Persons

    American Century Companies, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,407,790.00
    6Shared Voting Power

    7Sole Dispositive Power

    7,666,991.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,666,991.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    29415F104


    1Names of Reporting Persons

    Stowers Institute for Medical Research
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,407,790.00
    6Shared Voting Power

    7Sole Dispositive Power

    7,666,991.00
    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,666,991.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Envista Holdings Corporation
    (b)Address of issuer's principal executive offices:

    200 S. Kraemer Boulevard, Building E, Brea, CA, 92821
    Item 2. 
    (a)Name of person filing:

    American Century Investment Management, Inc. American Century Companies, Inc. Stowers Institute for Medical Research
    (b)Address or principal business office or, if none, residence:

    4500 Main Street 9th Floor Kansas City, Missouri 64111
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    29415F104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    See the response(s) to Item 11 on the attached cover page(s).
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Various persons, including the investment companies and separate institutional investor accounts that American Century Investment Management, Inc. ("ACIM") serves as investment adviser, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that are the subject of this schedule. Except as may be otherwise indicated if this is a joint filing, not more than 5% of the class of securities that is the subject of this schedule is owned by any one client advised by ACIM.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    This Item identifies each subsidiary of American Century Companies, Inc. ("ACC"), which is controlled by the Stowers Institute for Medical Research, that is a beneficial owner of securities that are subject of this schedule (the "Subject Securities"). American Century Investment Management, Inc. ("ACIM") is a wholly-owned subsidiary of ACC and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Not applicable
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    Not applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    American Century Investment Management, Inc.
     
    Signature:American Century Investment Management, Inc.
    Name/Title:/s/ John Pak / Senior Vice President
    Date:02/14/2025
     
    American Century Companies, Inc.
     
    Signature:American Century Companies, Inc.
    Name/Title:/s/ John Pak / Senior Vice President
    Date:02/14/2025
     
    Stowers Institute for Medical Research
     
    Signature:Stowers Institute for Medical Research
    Name/Title:/s/ Richard W. Brown / Chairman
    Date:02/14/2025
    Exhibit Information

    EXHIBIT Each of the undersigned hereby agrees and consents to the execution and joint filing on its behalf by American Century Investment Management, Inc. of this Schedule 13G respecting the beneficial ownership of the securities which are the subject of this schedule. Dated this 14th day of February, 2025. AMERICAN CENTURY INVESTMENT MANAGEMENT, INC. ("ACIM") AMERICAN CENTURY COMPANIES, INC. ("ACC") By: _/s/ John Pak_________________ John Pak Senior Vice President, ACIM and ACC STOWERS INSTITUTE FOR MEDICAL RESEARCH, solely in its capacity as control entity of ACC By: _/s/ Richard W. Brown___________ Richard W. Brown Chairman

    Get the next $NVST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVST

    DatePrice TargetRatingAnalyst
    5/27/2025$23.00Neutral → Outperform
    Robert W. Baird
    12/4/2024$20.00Underperform
    Mizuho
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    10/8/2024$20.00Equal Weight
    Wells Fargo
    8/8/2024$23.00 → $16.00Overweight → Neutral
    JP Morgan
    4/26/2024$33.00 → $21.00Overweight → Equal-Weight
    Morgan Stanley
    2/26/2024$19.00Underperform
    Leerink Partners
    2/9/2024$30.00 → $23.00Buy → Hold
    Jefferies
    More analyst ratings

    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Envista Announces Participation in Stifel 2025 Jaws & Paws Conference

      BREA, Calif., May 22, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will participate in the Stifel 2025 Jaws & Paws Conference. The fireside chat will take place on Wednesday, May 28, 2025, from 1:50 – 2:20 pm ET. A live audio webcast of the event, along with an archived replay, will be available in the Investors section of the Envista website at https://investors.envistaco.com/.  ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS

      5/22/25 4:15:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Hitachi Digital Services Announces Five-Year Strategic IT Partnership with Envista

      DALLAS, May 15, 2025 /PRNewswire/ -- Hitachi Digital Services, the digital consultancy and technology services subsidiary of Hitachi, Ltd. (TSE: 6501), today announced a five-year agreement with Envista Holdings Corporation (NYSE:NVST) ("Envista"), a global leader in dental care, to deliver end-to-end IT managed services across Envista's operations in more than 60 countries. Following a highly competitive tendering process, Envista selected Hitachi Digital Services as its strategic IT partner to support its digital transformation and operational efficiency goals. Under this ag

      5/15/25 11:23:00 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Reports First Quarter 2025 Results

      BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%

      5/1/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Compass Diversified Announces Stephen Keller as Chief Financial Officer

      WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b

      8/26/24 6:00:00 AM ET
      $AVY
      $CODI
      $NVST
      Containers/Packaging
      Consumer Discretionary
      Home Furnishings
      Medical/Dental Instruments
    • Envista Holdings Corporation Announces Key Leadership Appointments

      BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an

      7/15/24 4:10:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Financials

    Live finance-specific insights

    See more
    • Envista Reports First Quarter 2025 Results

      BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%

      5/1/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Schedules First Quarter 2025 Earnings Call

      BREA, Calif., April 8, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2025 on Thursday, May 1, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You ca

      4/8/25 4:15:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Reports Fourth Quarter 2024 Results

      BREA, Calif., Feb. 5, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2024. "In Q4 2024, Envista delivered results that were in line with expectations, indicating that our focus on growth, operations, and people is having a positive impact," said Paul Keel, Envista's CEO.  "2024 was a transition year for our company.  After a challenging first half, we took actions over the last two quarters to position ourselves for improved performance moving forward.  While we still have much more to do, we're encourag

      2/5/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Envista Holdings Corporation

      SC 13G - Envista Holdings Corp (0001757073) (Subject)

      11/8/24 12:09:03 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

      SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

      2/15/24 10:19:33 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Envista Holdings Corporation

      SC 13G - Envista Holdings Corp (0001757073) (Subject)

      2/14/24 4:08:38 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Keel Paul A covered exercise/tax liability with 12,787 shares, decreasing direct ownership by 3% to 401,652 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      5/27/25 4:45:59 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Chief Accounting Officer Kaabi Faez C covered exercise/tax liability with 4,319 shares and was granted 9,685 shares, increasing direct ownership by 12% to 49,996 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      2/27/25 5:27:45 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SVP, Strategy & Bus. Dev. Reis Mischa covered exercise/tax liability with 3,813 shares and was granted 8,475 shares, increasing direct ownership by 11% to 47,382 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      2/27/25 5:27:34 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    SEC Filings

    See more
    • SEC Form SD filed by Envista Holdings Corporation

      SD - Envista Holdings Corp (0001757073) (Filer)

      5/30/25 4:39:21 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Envista Holdings Corporation

      SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)

      5/15/25 4:27:38 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Envista Holdings Corporation

      10-Q - Envista Holdings Corp (0001757073) (Filer)

      5/1/25 4:17:13 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      8/14/24 4:40:20 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      8/13/24 6:01:10 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      11/20/23 5:49:32 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Envista upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Envista from Neutral to Outperform and set a new price target of $23.00

      5/27/25 9:05:49 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Envista with a new price target

      Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00

      12/4/24 7:46:09 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Envista from Underperform to Market Perform and set a new price target of $23.00 from $16.00 previously

      10/31/24 6:27:39 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care